

Speedy™ Human CCL7/MCP-3 One-Step ELISA Kit Datasheet

Please read it entirely before use

Catalogue Number: SE50226

Size: 96T

Sensitivity: 5.8 pg/mL

Range: 31.25 -2000 pg/mL

Usage: For the quantitative detection of human CCL7/MCP-3 concentrations in serum, plasma and cell culture supernatant.


This product is for research use only and not for use in human or animal therapeutic or diagnostic.

| Table of content | page |
|----------------------------------|-------------|
| 1. Background | 3 |
| 2. Principle | 3 |
| 3. Required Materials | 3 |
| 4. Kit Components and Storage | 4 |
| 5. Safety Notes | 4 |
| 6. Sample Collection and Storage | 4 |
| 7. Regent Preparation | 5 |
| 8. Assay Procedure Summary | 6 |
| 9. Validation Data | 8 |
| 9.1 Standard curve | 8 |
| 9.2 Precision | 9 |
| 9.3 Recovery | 9 |
| 9.4 Sample values | 9 |
| 9.5 Sensitivity | 10 |
| 9.6 Linearity | 10 |
| 9.7 Specificity | 10 |
| 10. References | 11 |

1. Background

The chemokine CCL7 (MCP3) is a chemotactic factor and potent attractant of monocytes firstly characterized from the culture supernatants of MG-63 osteosarcoma cells. CCL7 is known to promote the recruitment of many innate immune cell types including monocytes and neutrophils to sites of bacterial and viral infection and eosinophils and basophils to sites of allergic inflammation. CCL7 is expressed at low levels in endothelial cells, fibroblasts and mononuclear cells and upregulated by various stimuli including viruses, type I or type II interferons (IFNs). CCL7 (MCP-3) mediates effects on a host of innate and adaptive immune cell types through binding to numerous receptors including CCR1, CCR2, CCR3, CCR5, and CCR10. Various studies have shown that tumor cells and stromal cells also produce high levels of CCL7, while the specific response element and signaling pathways involved are not entirely clear.

2. Principle



An anti-tag antibody is pre-coated onto the bottom of wells. After adding antigen or samples, Tagged-Capture antibody and HRP-conjugated detection antibody, a sandwich complex is formed in the solution. TMB acts as a HRP substrate, and the solution color will change from colorless to blue. A stop solution containing sulfuric acid turns the solution yellow. The color intensity is proportional to the quantity of bound protein, which is measurable at 450 nm with the correction wavelength set at 630 nm.

3. Required Materials

- 3.1 A microplate reader capable of measuring absorbance at 450 nm with the correction wavelength set at 630 nm.
- 3.2 Calibrated, adjustable precision pipettes and disposable plastic tips. A manifold multi-channel pipette is recommended for large assays.
- 3.3 Plate washer: automated or manual.
- 3.4 Absorbent paper towels.
- 3.5 Glass or plastic tubes to prepare standard and sample dilutions.
- 3.6 Beakers and graduated cylinders.
- 3.7 Log-log or semi-log graph paper or computer and software for ELISA data analysis. A four-parameter logistic (4-PL) curve-fit is recommended. Proteintech data analysis website, <https://www.ptgcn.com/products/elisa-kits/>.
- 3.8 Microplate thermostatic shaker.

4. Kit Components and Storage

| | | |
|--|-----------|---|
| Microplate - 96 well microplate precoated an anti-tag antibody (8 well × 12 strips) | 1 plate | Unopened Kit: Store at 2-8°C for 6 months or -20°C for 12 months. Opened Kit: All reagents stored at 2-8°C for 7 days. Please use a new standard for each assay. |
| Protein standard - 4000 pg/bottle; lyophilized | 2 bottles | |
| Capture antibody (100×) - 60 µL/vial* | 1 vial | |
| Detection antibody, HRP-conjugated (100×) - 60 µL/vial* | 1 vial | |
| Sample Diluent PT 4B1 - 30 mL/bottle. For human serum and plasma. | 1 bottle | |
| Sample Diluent PT 4B1-em - 30 mL/bottle. For cell culture supernatant. | 1 bottle | |
| Detection Diluent - 15 mL/bottle | 1 bottle | |
| Wash Buffer Concentrate (20×) - 30 mL/bottle | 1 bottle | |
| Tetramethylbenzidine Substrate (TMB) - 12 mL/bottle | 1 bottle | |
| Stop Solution - 12 mL/bottle | 1 bottle | |
| Plate Cover Seals | 4 pieces | |

* Centrifugation immediately before use

5. Safety Notes

- 5.1 Avoid any skin and eye contact with Stop Solution and TMB. In case of contact, wash thoroughly with water.
- 5.2 Do not use the kit after the expiration date.
- 5.3 Do not mix or substitute reagents or materials from other kit lots or other sources.
- 5.4 Be sure to wear protective equipment such as gloves, masks and goggles during the experiment.
- 5.5 When using an automated plate washer, adding a 30 second soak period following the addition of Wash Buffer to improve assay precision

6. Sample Collection and Storage

- 6.1 Serum: Allow blood samples to clot for 30 minutes, followed by centrifugation for 15 minutes at 1000×g. Clear serum can be assayed immediately or aliquoted and stored at -20°C. Avoid repeated freeze-thaw cycles.
- 6.2 Plasma: Use EDTA, heparin, or citrate as an anticoagulant for plasma collection. Centrifuge for 15 minutes at 1000×g within 30 minutes of collection. The plasma can be assayed immediately or aliquoted and stored at -20°C. Avoid repeated freeze-thaw cycles.
- 6.3 Cell Culture Supernatant: Remove particulates by centrifugation for 5 minutes at 500×g and assay immediately or aliquot and store samples at ≤ -20°C. Avoid repeated freeze-thaw cycles.

7. Regent Preparation

7.1 Wash Buffer (1X): If crystals have formed in the concentrate, warm to room temperature and mix gently until the crystals have completely dissolved. Add 30 mL of Wash Buffer Concentrate(20X) to 570 mL deionized or distilled water to prepare 1X Wash Buffer.


7.2 Antibody Cocktail (1X): Dilute 100X capture antibody and 100X HRP-conjugated detection antibody using Detection Diluent prior to assay. Suggested 1:100 dilution: 50 μ L 100X capture antibody + 50 μ L 100X Detection Antibody, HRP-conjugated + 4,900 μ L Detection Diluent. Mix gently but thoroughly.

7.3 Sample Dilution: Different samples should be diluted with corresponding Sample Diluent, samples may require further dilution if the readout values are higher than the highest standard OD reading. Variations in sample collection, processing and storage may affect the results of the measurement.

Recommended Dilution for different sample types: 1:2 is recommended for human serum, plasma and cell culture supernatant.

7.4 Standard Serial Dilution:

For human serum and plasma, add 2 mL Sample Diluent PT 4B1 in protein standard. For cell culture supernatant, add 2 mL Sample Diluent PT 4B1-em in protein standard.



| | | | | | | | |
|--|-------------------------------|-------------|-------------|-------------|-------------|-------------|-------------|
| Add # μ L of Standard diluted in the previous step | — | 500 μ L | 500 μ L | 500 μ L | 500 μ L | 500 μ L | 500 μ L |
| # μ L of Sample Diluent PT 4B1 or PT 4B1-em | 2000 μL | 500 μ L | 500 μ L | 500 μ L | 500 μ L | 500 μ L | 500 μ L |
| | "sd7" | "sd6" | "sd5" | "sd4" | "sd3" | "sd2" | "sd1" |

8. Assay Procedure Summary

Bring all reagents to room temperature before use (Detection antibody, HRP-conjugated antibody can be used immediately). To avoid cross-contamination, change pipette tips between additions of each standard level, between sample additions, and between reagent additions. Also, use separate reservoirs for each reagent.

8.1 Preset the layout of the microplate, including control group, standard group and sample group, take out the required number of microplate strips and return excess strips to the foil pouch containing the drying reagent pack and reseal; store at 4°C immediately. Microplate strips should be used in one week.

8.2 Add 50 µL standard or sample to appropriate wells. To avoid high background always add samples or standards to the well before the addition of antibody cocktail.

8.3 Add 50 µL 1× Antibody Cocktail solution (refer to Reagent Preparation 7.2) to each well. Seal plate with cover seal and incubate at 37°C on a microplate thermostatic shaker set at 400 rpm for 1 hour (incubate at 37°C for 2 hours is recommended if thermostatic shaker is not available) .

8.4 Wash

1) Gently remove the cover seal. Discard the liquid from wells by aspirating or decanting. Remove any residual solution by tapping the plate a few times on fresh paper towels.

2) Wash 4 times with 1× Wash Buffer, using at least 350-400 µL per well. Following the last wash, firmly tap plates on fresh towels 10 times to remove residual Wash Buffer. Avoid getting any towel fibers in the wells or wells drying out completely.

8.5 Add 100 µL TMB substrate solution to each well, protected from light. Incubate at 37°C on a microplate thermostatic shaker set at 400 rpm for 15 to 20 minutes. (Substrate Solution should remain colorless until added to the plate.)

8.6 Add 100 µL Stop Solution to each well in the same order as addition of the TMB substrate. Note: Avoid skin and eye contact with the Stop solution.

8.7 Read results immediately on a microplate reader at a wavelength of 450 nm. If possible, perform a double wavelength readout (450 nm and 630 nm).

8.8 Data analysis: Calculate the average of the duplicate readings (OD value) for each standard and sample, and subtract the average of the zero standard absorbance. Construct a standard curve by plotting the mean absorbance for each standard on the y-axis against the concentration on the x-axis, four-parameter logistic curve-fit (4-PL) analysis is recommended. If the samples have been diluted, the fitting result must be multiplied by the dilution factor used.

Procedure summary

Add 50 μ L standard or sample to appropriate wells



Add 50 μ L antibody cocktail solution (1x) to each well



Incubate at 37 $^{\circ}$ C on a microplate thermostatic shaker set at 400 rpm for 1 hour



Aspirate and wash each well four times with 400 μ L 1 x Wash Buffer



Add 100 μ L TMB substrate solution to each well



Incubate at 37 $^{\circ}$ C on a microplate thermostatic shaker set at 400 rpm for 15minutes




Add 100 μ L Stop Solution to each well and Read OD immediately


9. Validation Data

9.1 Standard curve

These standard curves are provided for demonstration only. A standard curve should be generated for each set of samples assayed.



| (pg/mL) | O.D | Average | Corrected |
|---------|------------------|---------|-----------|
| 0 | 0.0122 0.0149 | 0.0136 | - |
| 31.25 | 0.073 0.0648 | 0.0689 | 0.0554 |
| 62.5 | 0.1258 0.121 | 0.1234 | 0.1099 |
| 125 | 0.2349 0.2245 | 0.2297 | 0.2162 |
| 250 | 0.4426 0.4464 | 0.4445 | 0.4310 |
| 500 | 0.8465 0.846 | 0.8463 | 0.8327 |
| 1000 | 1.6791 1.6135 | 1.6463 | 1.6328 |
| 2000 | 2.6371 2.5657 | 2.6014 | 2.5879 |



| (pg/mL) | O.D | Average | Corrected |
|---------|------------------|---------|-----------|
| 0 | 0.0628 0.0626 | 0.0627 | - |
| 31.25 | 0.1092 0.1049 | 0.1071 | 0.0444 |
| 62.5 | 0.1693 0.1543 | 0.1618 | 0.0991 |
| 125 | 0.2609 0.2561 | 0.2585 | 0.1958 |
| 250 | 0.473 0.4243 | 0.4487 | 0.3860 |
| 500 | 0.8513 0.7538 | 0.8026 | 0.7399 |
| 1000 | 1.423 1.3964 | 1.4097 | 1.3470 |
| 2000 | 2.5066 2.4438 | 2.4752 | 2.4125 |

9.2 Precision

Intra-assay Precision (Precision within an assay) Three samples of known concentration were tested 8 times on one plate to assess intra-assay precision.

Inter-assay Precision (Precision between assays) Three samples of known concentration were tested in 16 separate assays to assess inter-assay precision.

| Intra-assay Precision | | | | | Inter-assay Precision | | | | |
|-----------------------|---|--------------|------|-----|-----------------------|----|--------------|------|-----|
| Sample | n | Mean (pg/mL) | SD | CV% | Sample | n | Mean (pg/mL) | SD | CV% |
| 1 | 8 | 1,040.6 | 13.3 | 1.3 | 1 | 16 | 1,039.5 | 19.4 | 1.9 |
| 2 | 8 | 250.8 | 3.6 | 1.4 | 2 | 16 | 252.5 | 4.6 | 1.8 |
| 3 | 8 | 127.6 | 3.6 | 2.8 | 3 | 16 | 128.4 | 2.9 | 2.3 |

9.3 Recovery

The recovery of human CCL7/MCP-3 spiked to three different levels throughout the range of the assay in various matrices was evaluated.

| Sample Type | | Average% of Expected | Range (%) |
|--------------------------|-----|----------------------|-----------|
| Human serum | 1:2 | 80 | 80-81 |
| Cell culture supernatant | 1:2 | 103 | 101-104 |
| | 1:4 | 101 | 98-106 |

9.4 Sample values

Human serum - Sixteen samples were evaluated for detectable levels of human CCL7/MCP-3 in this assay. All samples measured less than the lowest human CCL7/MCP-3 standard, 31.25 pg/mL.

Cell culture supernatant:

MG-63 human osteosarcoma cells were cultured in DMEM supplemented with 10% fetal bovine serum, 2.5 mM L-glutamine, 100 U/mL penicillin, and 100 µg/mL streptomycin sulfate. An aliquot of the cell culture supernate was removed, assayed for human CCL7/MCP-3, and measured 60.6 pg/mL.

human peripheral blood mononuclear cells (1×10^6 cells/mL) were cultured in DMEM supplemented with 10% fetal bovine serum, 5 µM β-mercaptoethanol, 2 mM L-glutamine, 100 U/mL penicillin, and 100 µg/mL streptomycin sulfate. Cells were cultured unstimulated or stimulated with 10 µg/mL PHA for 1 day. Aliquots of the cell culture supernates were removed and assayed for levels of human CCL7/MCP-3.

| Condition | Day 1 (pg/mL) |
|--------------|---------------|
| Unstimulated | ND |
| Stimulated | 660.8 |

ND*=Non-detectable

9.5 Sensitivity

The minimum detectable dose of human CCL7/MCP-3 is 5.8 pg/mL. This was determined by adding two standard deviations to the concentration corresponding to the mean O.D. of 20 zero standard replicates.

9.6 Linearity

To assess the linearity of the assay, human serum samples were spiked with high concentrations of human CCL7/MCP-3 and diluted with the appropriate **Sample Diluent** to produce samples with values within the dynamic range of the assay. Cell culture supernatant samples were diluted with the appropriate **Sample Diluent** to produce samples with values within the dynamic range of the assay.

| | | Human serum (Sample Diluent PT 4B1) | Cell culture supernatant (Sample Diluent PT 4B1-em) |
|------|----------------------|--|--|
| 1:2 | Average% of Expected | 89 | 100 |
| | Range (%) | 88-90 | - |
| 1:4 | Average% of Expected | 88 | 87 |
| | Range (%) | 84-91 | 85-89 |
| 1:8 | Average% of Expected | 104 | 72 |
| | Range (%) | 102-106 | 70-74 |
| 1:16 | Average% of Expected | 112 | - |
| | Range (%) | 106-118 | - |

9.7 Specificity

This assay recognizes natural and recombinant human CCL7/MCP-3.

The following factors prepared at 50 ng/mL were assayed and exhibited no cross-reactivity or interference.

Recombinant human:

CTACK

HCC-1

HCC-4

MIP-1 α

A sample containing 50 ng/mL of the recombinant human MCP-4 reads as 91.7 pg/mL (0.18% cross-reactivity).

A sample containing 50 ng/mL of the recombinant human MDC reads as 64.4 pg/mL (0.13% cross-reactivity).

A sample containing 50 ng/mL of the recombinant human Eotaxin reads as 257.3 pg/mL (0.51% cross-reactivity).

A sample containing 50 ng/mL of the recombinant human MCP-2 reads as 37.7 pg/mL (0.08% cross-reactivity).

10. References

1. Van Damme, J et al. The Journal of experimental medicine vol. 176,1 (1992): 59-65.
2. Menten, P et al. European journal of immunology vol. 29,2 (1999): 678-85.
3. Griffith, Jason W et al. Annual review of immunology vol. 32 (2014): 659-702.
4. Ben-Baruch, A et al. The Journal of biological chemistry vol. 270,38 (1995): 22123-8.
5. Lee, Pui Y et al. The American journal of pathology vol. 175,5 (2009): 2023-33.